Previous 10 | Next 10 |
2024-01-16 10:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Verastem Oncology (Nasdaq: VSTM) (the “Company), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in a fireside chat at the B. Riley Securities 4 th Annual Oncology Conference on Thursday, Janua...
Investigational New Drug (IND) Submission Planned for GFH375/VS-7375 in H1 2024 No FDA Approved Therapies Available Targeting KRAS G12D, the Most Prevalent KRAS Mutation in Human Cancer Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company c...
2023-12-13 12:22:29 ET More on Verastem Verastem: Potential Accelerated Approval Filing In H1 2024 Verastem: Signs Of Life For A Beaten-Down Equity Seeking Alpha’s Quant Rating on Verastem Historical earnings data for Verastem Financial informa...
RAMP 301 Is Evaluating the Combination of Avutometinib and Defactinib vs Investigator’s Choice of Therapy Reported Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability Profile with the Combination Company Intends ...
2023-11-22 14:22:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through...
2023-11-18 12:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Developed in Partnership with Healthcare Professionals and Patients, Let’s Talk About LGSOC Provides Information Related to the Biology, Diagnosis, Treatment, and Patient Experience Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicine...
2023-11-12 01:40:08 ET Summary An application for Accelerated Approval of avutometinib + defactinib for low-grade serous ovarian cancer patients is expected in the first half of 2024. The ongoing RAMP-301 study is being done to keep avutometinib + defactinib for LGSC on the market...
2023-11-09 09:02:09 ET More on Verastem Verastem: Signs Of Life For A Beaten-Down Equity RAMPing Up Hope: Verastem's Cancer Crusade Verastem, China's GenFleet to collaborate on RAS pathway-driven cancer drugs For further details see: Verastem files $300M ...
News, Short Squeeze, Breakout and More Instantly...
2024-05-18 20:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Plan to announce topline RAMP 201 data with the start of planned rolling NDA submission for avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer in Q2 2024 FDA Fast Track Designation granted for avutometinib in combination with adagrasib for the treatment o...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 20...